Sylvia Adams
西尔维亚·亚当斯
MD
Director of Breast Cancer Medicine Program乳腺癌药物治疗项目主任
👥Biography 个人简介
Sylvia Adams is a pioneer in TNBC immunotherapy at NYU Langone, whose early work on tumor-infiltrating lymphocytes shaped understanding of immune contexture in breast cancer. She has led multiple immunotherapy trials and is a leading voice in precision breast oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tumor-Infiltrating Lymphocytes in TNBC
Established TILs as a prognostic and predictive biomarker in TNBC, influencing patient selection for immunotherapy and clinical trial design.
Immunotherapy Combinations in Breast Cancer
Led clinical trials of checkpoint inhibitors in TNBC, contributing evidence that informs the integration of immunotherapy into early and metastatic treatment.
Representative Works 代表性著作
Atezolizumab plus nab-paclitaxel in metastatic TNBC (IMpassion130)
New England Journal of Medicine (2018)
Key trial showing atezolizumab benefit in PD-L1+ TNBC, supporting first-line immunotherapy use and biomarker-driven selection.
Prognostic significance of TILs in TNBC
Journal of Clinical Oncology (2014)
Demonstrated TILs predict improved survival in TNBC, establishing immune infiltration as a critical prognostic variable.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 西尔维亚·亚当斯 的研究动态
Follow Sylvia Adams's research updates
留下邮箱，当我们发布与 Sylvia Adams（NYU Langone Health / Perlmutter Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment